Tumor Model and Biospecimen Repository Core

肿瘤模型和生物样本库核心（核心C）总结 肿瘤模型和生物样本库核心（核心C）由阿德尔K博士领导。El-Naggar（核心负责人）和Dr. Jeffrey Myers（核心联合负责人）将为H-CARR研究人员提供一个集中的设施，以确保 系统收集、处理、储存和分配外周血、替代血和专业血 样本和头颈部鳞状细胞癌（HNSCC）的样本， 并在贝勒大学德克萨斯大学医学博士安德森癌症中心（MD安德森）进行了随访。 医学（英语：Medicine）核心C还提供专家准备和高质量的样品和辅助分配 H-CARR研究人员优化患者材料利用的技术。采购和分配 将样本分发给各个研究者将遵循H-CARR中心执行官制定的指南 领导委员会和遵守HIPAA。核心C领导层将提供详细的病理检查结果， 通过与H-2000网络连接的安全病理学数据库系统，对研究者的所有肿瘤样本进行评估。 卡尔、数据库和服务器。核心C将执行专门的服务，包括组织微阵列（TMA） 构建、组织中的定性和定量生物标志物分析[例如，免疫组织化学（IHC）， Western印迹]和非组织（例如，基于血液的细胞因子谱）标本、核酸提取物，以及 细胞系的开发和维持。核心C还将提供良好表征的、基因组学上的 经验证的头颈癌细胞系，充分表征的患者来源的异种移植物（PDX）模型，以及 免疫抑制或同源小鼠异位和原位动物模型及原位肿瘤 HNSCC的模型。核心C的领导层和人员及其集中组织将 确保向所有H-CARR研究者提供最高质量的组织样本和相关分析， 参与其他NIH/NCI赞助项目的研究人员。

Tumor Model and Biospecimen Repository Core (Core C) SUMMARY Tumor Model and Biospecimen Repository Core (Core C) led by Dr. Adel K. El-Naggar (Core Leader) and Dr. Jeffrey Myers (Core Co-Leader), will provide H-CARR investigators with a centralized facility that ensures the systematic collection, processing, storage, and distribution of peripheral blood, surrogate and specialized specimens, and samples of head and neck squamous cell carcinoma (HNSCC) from patients diagnosed, treated, and followed at The University of Texas MD Anderson Cancer Center (MD Anderson) at Baylor College of Medicine (BCM). Core C also provides expert preparation and distribution of high-quality samples and ancillary techniques to optimize utilization of patients’ materials by H-CARR investigators. Procurement and distribution of the samples to individual investigators will follow the guidelines established by the H-CARR Center Executive Leadership Committee and in compliance with HIPAA. Core C leadership will provide detailed pathologic evaluation of all tumor samples to investigators through the secure pathology database system linked to the H- CARR, database, and server. Core C will perform specialized services, including tissue microarray (TMA) construction, qualitative and quantitative biomarker analyses both in tissue [e.g., immunohistochemistry (IHC), Western blotting] and non-tissue (e.g., blood-based cytokine profiles) specimens, nucleic acid extractions, and development and maintenance of cell lines. Core C will also provide well-characterized, genomically authenticated head and neck cancer cell lines, well-characterized patient-derived xenograft (PDX) models, and heterotopic and orthotopic animal models in immunosuppressed or syngeneic mice and autochthonous tumor models of HNSCC to investigators. The leadership and personnel of Core C and its centralized organization will ensure the highest quality tissue samples and related analyses to all H-CARR investigators and to collaborating researchers participating in other NIH/NCI-sponsored programs.